ARLNC1: A Potential Drug Target and Biomarker (G100996425)

Target Name: ARLNC1

NCBI ID: G100996425

ARLNC1

Other Name(s): ARLNC1 variant 1 | LINC02170 | PRCAT47 | Androgen receptor regulated long noncoding RNA 1, transcript variant 1 | androgen receptor regulated long noncoding RNA 1

ARLNC1: A Potential Drug Target and Biomarker

Autophagy is a critical intracellular process that plays a crucial role in maintaining cellular health and longevity. The autophagy-mediated cell death pathway is a natural response to environmental stressors, such as starvation, UV radiation, and hormonal changes, and is essential for maintaining cellular homeostasis. However, when the autophagy pathway becomes disrupted due to mutations or over-expression of genes, it can lead to cellular stress, including the development of cancer.

One of the key genes involved in autophagy is ARLNC1, which encodes a protein that is critical for the formation and maintenance of autophagy. In this article, we will discuss ARLNC1 as a potential drug target and biomarker for cancer.

ARLNC1: Structure and Function

ARLNC1 is a gene that encodes a protein of approximately 18 kDa. The protein is composed of multiple domains, including an N-terminal transmembrane domain, a coiled-coil domain, and a C-terminal T-loop domain. The N-terminal domain is responsible for the formation of the protein's transmembrane domain, while the coiled-coil domain is responsible for the protein's stability and functions as a molecular chaperone. The T-loop domain is involved in the regulation of protein stability and functions as a critical signaling molecule.

ARLNC1 is a key gene that is involved in the formation and maintenance of autophagy. Autophagy is a critical intracellular process that is essential for the regulation of cellular stress, including the development of cancer. The ARLNC1 protein plays a critical role in the formation and maintenance of autophagy by regulating the formation of the autophagosome, which is the cellular organelle responsible for autophagy.

ARLNC1 has also been shown to be involved in the regulation of cellular processes that are critical for the development of cancer. For example, studies have shown that ARLNC1 is involved in the regulation of cell growth, angiogenesis, and the transformation of cancer cells. In addition, studies have also shown that ARLNC1 is involved in the regulation of cell survival and that its expression is associated with the development of cancer.

ARLNC1 as a Drug Target

ARLNC1 is a potential drug target for cancer because of its involvement in the regulation of autophagy and the development of cancer. Drugs that target ARLNC1 have the potential to inhibit its function and disrupt its role in the development of cancer.

One approach to targeting ARLNC1 is to use small molecules that inhibit the formation of autophagosomes. Small molecules that inhibit the formation of autophagosomes would disrupt the ability of ARLNC1 to regulate the formation of autophagy, which would have the potential to inhibit the development of cancer.

Another approach to targeting ARLNC1 is to use drugs that target its function as a molecular chaperone. Molecular chaperones are proteins that help to regulate the formation and stability of other proteins, and ARLNC1 is involved in the regulation of protein stability. Drugs that target ARLNC1's function as a molecular chaperone would disrupt its ability to regulate the formation and stability of other proteins, which would have the potential to inhibit the development of cancer.

ARLNC1 as a Biomarker

ARLNC1 has also been shown to be involved in the regulation of cellular processes that are critical for the development of cancer. In addition, studies have shown that ARLNC1 is involved in the regulation of cell survival, which is a critical factor in the development

Protein Name: Androgen Receptor Regulated Long Noncoding RNA 1

The "ARLNC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARLNC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets